Biogen to halt sales and development of controversial Alzheimer's drug Aduhelm
Biogen will stop sales and development of its controversial Alzheimer’s drug Aduhelm, walking away from a drug that was approved against outside experts’ advice, led …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
